3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
4
Colorectal Neoplasms
3
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Solid Tumors
1
Rectal Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Brain Neoplasms
1
Advanced Solid Tumor
1
Interventions
Oxaliplatin
14
Leucovorin
12
Fluorouracil
12
Cetuximab
10
Bevacizumab
9
pembrolizumab
7
Specimen Handling
7
Nivolumab
6
Magnetic Resonance Spectroscopy
6
Irinotecan
5
encorafenib
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
fludarabine
3
cemiplimab
3
Laparoscopy
3
Folfox protocol
3
Early Intervention, Educational
3
Cyclophosphamide
3
Carboplatin
3
Capecitabine
3
Biopsy
3
trifluridine tipiracil drug combination
2
pertuzumab
2
durvalumab
2
dehydroftorafur
2
aldesleukin
2
X-Rays
2
Watchful Waiting
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
adagrasib
×
90 days
×
Clear all
NCT04793958
2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3
Active not recruiting
461 enrolled